September 29, 2020 11:17 AM EDTUpdated 02:08 PM
R&D

My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

Max Gelman

Senior Editor

My­ovant $MY­OV has been prep­ping re­l­u­golix for ad­vanced prostate can­cer over the last sev­er­al months, look­ing to im­prove up­on the old stan­dard in Ab­b­Vie …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times